This study assesses the performance and turnaround time (TAT) of the Biocartis Idylla platform for ultrarapid BRAF p.V600E detection across various preparations, emphasizing the use of residual CytoLyt material (supernatant cell-free DNA [ScfDNA]).<h4>Methods</h4>All histologically confirmed cases of aggressive thyroid carcinomas received for Idylla testing were identified. The gene discussed is BRAF; the disease is thyroid gland carcinoma.